Call Us for Support
+91 9654860915
Finding access to medicine unapproved in your home country can feel overwhelming. We’re here to help you navigate the process, from your initial request to procurement coordination.
Submit your details and prescription to get started.Register today to get started on your medicine access journey.
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
Ready to proceed? Order Anlotinib on our secure patient portal to submit your prescription, upload documents and track your approval status.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Regulatory Approval:
Your Trustworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Anlotinib is a once-a-day capsule used for several kinds of advanced cancer, most often lung cancer and soft tissue sarcoma. It is made in China by Chia Tai Tianqing Pharmaceutical Group (part of Sino Biopharm) under the brand name 福可维 (Focus V®), and was co-developed with Advenchen Laboratories. China's National Medical Products Administration (NMPA) first approved it in May 2018, for lung cancer that had kept growing after chemotherapy.
The current Chinese label (updated 2026) lists these uses in adults:
It is a prescription cancer medicine and should only be started and managed by an oncologist.
Tumours need a steady blood supply to grow, and they send out signals to build new vessels. This capsule is a multi-target tyrosine kinase inhibitor: it blocks the VEGFR1–3, FGFR1–4 and PDGFR α/β receptors that drive that vessel growth, and also c-Kit and RET, which some cancer cells use to multiply. Starving the tumour of new vessels slows it down.
Its first approval rested on ALTER0303, a phase 3 study in China of 437 people with advanced NSCLC that had come back after two or more lines of chemotherapy. Participants were randomised two to one to the capsule or a placebo. Median overall survival was 9.46 months against 6.37 months (hazard ratio 0.70), and the time before the cancer grew again rose from 1.40 to 5.37 months. About 81% of treated patients had their disease shrink or stay stable, compared with 37% on placebo.
Your oncologist decides which combination, if any, is right for you and how long treatment continues.
This information is not a treatment plan. For personalized medical advice, consult your doctor and refer to the full prescribing information.
Who should not take it: people allergic to any ingredient, those with central squamous lung cancer that has cavities or a high risk of major coughing up of blood, people with severe liver or kidney impairment, and women who are pregnant or breastfeeding.
Other effects: tiredness, diarrhoea, poor appetite, raised blood fats, mouth sores and, rarely, a brain swelling syndrome called RPLS (headache, fits, vision changes). Strong CYP3A4 or CYP1A2 inhibitors and inducers can change blood levels, and grapefruit should be avoided. Safety in children under 18 has not been established.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
The capsules can be brought in only in the patient's own name, by the patient or a government hospital, following India's rules for importing unapproved medicines. Please keep ready:
Only after we have checked the prescription and, if required, the import permit.
No. It is approved in China only. CDSCO has not approved it, so it is not stocked by Indian pharmacies. The US FDA has not approved it, and a European application (under the name catequentinib) was withdrawn in October 2026 after a negative opinion.
A legal way to obtain it is the Named Patient Program (NPP), which lets one named patient import a medicine that is not registered in India against a doctor's prescription. We also handle other China-approved cancer tablets that block blood vessel growth, such as vorolanib for kidney cancer and famitinib.
It can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient's treating hospital. Orders are confirmed only after receipt of a valid doctor's prescription and an import permit, where applicable.
NamedPatientProgram.com (NPP) sources this medicine through the manufacturer's authorised supply channels in China and arranges supply to patients, doctors, and hospitals under applicable legal provisions. The label asks for storage in the sealed pack, away from light and moisture, at no more than 25°C, so the boxes travel unopened under temperature-controlled shipping. Since one cycle uses 14 capsules, we usually plan supply for one or more full cycles at a time. All prescriptions are dispensed and checked by registered pharmacists and dispatched from New Delhi, India, after legal requirements are fulfilled.
For the current cost in India and availability, contact NPP via WhatsApp at +91 98104 69557 | Toll-Free: 1800-1200-365 or email info@namedpatientprogram.com.
Patients across India can access this medicine through regulated import pathways, with delivery to the patient or treating hospital on a valid oncologist's prescription.
Large cancer hospitals in Delhi treat lung cancer and sarcoma patients from across the north, and dispatch from New Delhi keeps transit time short.
Oncologists in Mumbai can send the prescription and scan reports, and the capsules are delivered to the patient or the hospital pharmacy.
Patients in Bangalore receive a written quote first, and nothing is ordered until the family agrees.
For patients treated in Chennai, we time each shipment so the next 21-day cycle can start without a break.
Thoracic oncology teams in Hyderabad can request the capsules for a named patient after earlier chemotherapy has stopped working.
Families in Kolkata and the north-east receive tracking updates from dispatch until the box is in their hands.
Sarcoma and lung cancer patients in Pune can use the same documented import route as in the metros.
Doctors in Ahmedabad can share the treatment history with us, and we confirm what paperwork is still needed.
Patients treated at hospitals in Vellore can have the supply sent to the hospital so it fits in with their clinic reviews.
We deliver to patients and cancer centres across Punjab, Haryana and Himachal Pradesh through Chandigarh.
Patients across Uttar Pradesh can receive the medicine at home or at their treating hospital in Lucknow.
Patients in Kerala can have each cycle's capsules delivered to Kochi and nearby towns.
Access can also be coordinated for patients in other Indian cities, subject to a valid prescription and regulatory requirements.
Written By
Nitin GoswamiDeputy Manager – Content & Social Media, Ikris Pharma Network
Sources: NMPA • CDSCO
Last Updated: 18 November 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message